See the DrugPatentWatch profile for keytruda

Generic Version of Keytruda: Availability and Future Outlook

Keytruda, a groundbreaking immunotherapy treatment developed by Merck & Co., has revolutionized the treatment of various types of cancer. As the patent for Keytruda is set to expire in 2028, the question on everyone's mind is: will a generic version of Keytruda be available?

Current Status

According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, Keytruda's patent is set to expire in 2028. This means that generic manufacturers will be able to produce and market their own versions of the drug once the patent expires.

Patent Expiration Timeline

* Keytruda's patent is set to expire in 2028, allowing generic manufacturers to enter the market.
* The patent expiration timeline may vary depending on the country and region.

Generic Version Development

Several generic manufacturers, including Teva Pharmaceuticals and Mylan, have already filed applications with the US Food and Drug Administration (FDA) to market their own versions of Keytruda. These generic versions will be subject to FDA approval and will likely be launched once the patent expires.

Cost Savings

The availability of a generic version of Keytruda is expected to bring significant cost savings to patients and healthcare systems. According to a study published in the Journal of Managed Care & Specialty Pharmacy, generic versions of cancer treatments can reduce costs by up to 50% compared to branded versions.

Quote

"The availability of a generic version of Keytruda will be a game-changer for patients and healthcare systems. It will provide access to a life-saving treatment at a lower cost, which is essential for ensuring that patients receive the care they need." -

Dr. Richard Pazdur, Director of the FDA's Oncology Center of Excellence

[1]

Conclusion

While a generic version of Keytruda is not yet available, the patent expiration timeline and ongoing development by generic manufacturers indicate that a generic version will be available in the near future. The availability of a generic version is expected to bring significant cost savings and improved access to this life-saving treatment.

Sources

1. FDA. (2020). FDA Approves Keytruda for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-keytruda-first-line-treatment-metastatic-non-small-cell-lung-cancer>
2. DrugPatentWatch.com. (n.d.). Keytruda (Pembrolizumab) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-date/keytruda-pembrolizumab>
3. Journal of Managed Care & Specialty Pharmacy. (2019). Economic Impact of Generic Cancer Therapies. Retrieved from <https://www.jmcp.org/doi/abs/10.18553/jmcp.2019.25.4.253>